Janus Henderson Group PLC Trims Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Janus Henderson Group PLC lessened its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 96.7% in the third quarter, HoldingsChannel reports. The firm owned 23,319 shares of the company’s stock after selling 675,069 shares during the quarter. Janus Henderson Group PLC’s holdings in Pacira BioSciences were worth $351,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in PCRX. Innealta Capital LLC bought a new position in shares of Pacira BioSciences during the second quarter valued at approximately $50,000. nVerses Capital LLC grew its stake in shares of Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after buying an additional 1,600 shares during the last quarter. CWM LLC increased its position in Pacira BioSciences by 713.6% during the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after buying an additional 5,716 shares in the last quarter. Quest Partners LLC purchased a new position in Pacira BioSciences during the second quarter valued at $113,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Pacira BioSciences by 62.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock worth $134,000 after acquiring an additional 3,404 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Trading Up 0.3 %

NASDAQ:PCRX opened at $19.86 on Monday. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The company has a 50 day simple moving average of $17.27 and a two-hundred day simple moving average of $19.04. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Pacira BioSciences in a report on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Barclays dropped their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 12th. Royal Bank of Canada raised their price target on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Finally, Jefferies Financial Group upped their price objective on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and a consensus target price of $23.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.